Cortactin (Acetyl Lys235) Polyclonal Antibody BT-AP02136
Specifications
| 20ul / 50ul / 100ul |
Background:
CTTN is overexpressed in breast cancer and squamous cell carcinomas of the head and neck. Cortactin is localized in the cytoplasm and in areas of the cell-substratum contacts. This gene has two roles: (1) regulating the interactions between components of adherens-type junctions and (2) organizing the cytoskeleton and cell adhesion structures of epithelia and carcinoma cells. During apoptosis, cortactin is degraded in a caspase-dependent manner. The aberrant regulation of CTTN contributes to tumor cell invasion and metastasis. Three splice variants that encode different isoforms have been identified for CTTN.
Classification:
Primary antibody
Alternative names:
CTTN; EMS1; Src substrate cortactin; Amplaxin; Oncogene EMS1
Species reactivity:
Human;Mouse;Rat
Host:
Rabbit
Isotype:
IgG
Immunogen:
Synthesized acetyl-peptide derived from the Internal region of human Cortactin around the acetylation site of K235.
Concentration:
1 mg/ml
Molecular weight:
61636
Applications:
WB, ELISA
Storage:
-20°C for one year
More info:
Email: info@sobekbio.com
Orders:
Email: orders@sobekbio.com
Fine Biotech is an ISO9001:2008 Certified Company,offers a full line of quality research kits,which include ELISA Kits,related ELISA assistant reagents and more high quality antibodies, recombinant proteins. Fine Biotech technical support are delicated to providing with professional and friendly assistance for our customers. Strict and multiple quality control ensure that our products continue to successfully supply for the international market. Moreover, we strive to continuously improve the customer experience through comprehensive technical support. High quality,rapid turnaround and personal support for all FineTest services are guaranteed. Should you have any problems,or any ideas on ways that we can improve our service,please feel free to call upon us.Thank you for your interest in FineTest products and we look forward to supplying you in the near future.